| Literature DB >> 35216290 |
Xiaolan Fan1,2, Ziqiang Fan1, Ziyue Yang1, Tiantian Huang1, Yingdong Tong1, Deying Yang1,2, Xueping Mao1,2, Mingyao Yang1,2.
Abstract
The aging of mammals is accompanied by the progressive atrophy of tissues and organs and the accumulation of random damage to macromolecular DNA, protein, and lipids. Flavonoids have excellent antioxidant, anti-inflammatory, and neuroprotective effects. Recent studies have shown that flavonoids can delay aging and prolong a healthy lifespan by eliminating senescent cells, inhibiting senescence-related secretion phenotypes (SASPs), and maintaining metabolic homeostasis. However, only a few systematic studies have described flavonoids in clinical treatment for anti-aging, which needs to be explored further. This review first highlights the association between aging and macromolecular damage. Then, we discuss advances in the role of flavonoid molecules in prolonging the health span and lifespan of organisms. This study may provide crucial information for drug design and developmental and clinical applications based on flavonoids.Entities:
Keywords: aging; flavonoids; health span; macromolecular damage
Mesh:
Substances:
Year: 2022 PMID: 35216290 PMCID: PMC8879655 DOI: 10.3390/ijms23042176
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Basic structures of the major naturally occurring flavonoids.
Figure 2Diagram of the major influences and mechanisms by which macromolecular damage induces aging. Damage insults (genotoxic stress, oxidative stress, etc.) in genetic or environmental factors damage macromolecules (mainly including DNA, proteins, and lipids) during the aging process, causing intracellular damage to accumulate. At the same time, the repairability in the cell declines with aging, which causes the accumulation of unrepaired damage in the cell. Accumulated unrepaired damage can lead to mutations or chromosomal aberrations, leading to genome instability. Severely shortened telomeres activate the DNA repair and damage response (DDR) and cause cell senescence. Accumulated unrepaired damage affects autophagy and the ER-UPR and results in the loss of protein complex stoichiometry. Mitochondrial dysfunction is driven by NAD+ deprivation caused by nuclear DNA repair, mitochondrial autophagy defects induced by DNA damage, and changes in the expression of mtDNA polymerase that affect mtDNA replication. The accumulated unrepaired damage wreck the nutrient-sensing pathway, affecting repair and signal transduction. The accumulated unrepaired damage induces cell senescence and leads to the exhaustion of the stem cell pool through DDR-induced apoptosis, senescence, premature differentiation, and changes in the niche of stem cells. Cell senescence affects cell-to-cell communication through inflammatory cytokines and inhibitory growth signals.
Overview of the modulatory anti-aging effect of flavonoids and related mechanisms.
| Flavonoids | Structure | Targets | Activity | Lifespan | Reference |
|---|---|---|---|---|---|
| Senolytic | |||||
| Quercetin |
| Numerous (including PI3K) | ↓Senescent human cells in vitro; | 15–60% lifespan in mice and | [ |
| Fisetin |
| PI3K/AKT/mTOR | ↓Senescent human cells in vitro; | ~13% in mice, 23% in | [ |
| Luteolin |
| ROS, PGE2, COX2 | ↓Senescent human cells and SASP in vitro | No data | [ |
| Senomorphic | |||||
| Apigenin |
| NF-κB | ↓SASP in fibroblasts; | No data | [ |
| Kaempferol |
| IRAK1/IkBα/NF-κB p65 | ↓SASP in fibroblasts; | No data | [ |
| Others with antisenescence activity | |||||
| 4,4′Dimethoxychalcone |
| Autophagy | ↓Cell senescence; | Approximately 20% increase in | [ |
| Naringenin |
| SIRT1/LKB1/PGC1α/NF-κB | ↓Cardiac markers of aging-induced damage; | 22.62% increase in females of | [ |
| Genistein |
| NF-κB | ↓Proinflammatory genes expression; | No data | [ |
| Myricetin |
| FOXO | ↓HMW-Aβ-induced neurotoxicity; | 32.9% in increase | [ |
| Dihydromyricetin |
| FOXO/ | ↓Oxidative stress and inflammation-related senescence; | 16.07% increase in | [ |
| Epicatechin |
| Autophagy | ↓Cell senescence; | 7.1% increase in | [ |
| Nobiletin |
| Target RORs | ↓ROS; | 1 month | [ |
| Rutin |
| Insulin/IGF1 | ↓ROS and proinflammatory cytokines (TNF-α and IL-1β); | 32% increase HFD | [ |
| Hesperidin |
| Nrf2 | ↓ROS; | Extends the repilicative lifespan of the | [ |
| Theaflavin |
| Nrf2 | ↓Stem cell senescence; | Lifespan increase in | [ |
SASP: senescence-related secretion phenotype; AD: Alzheimer’s disease; ATGs: autophagy-related genes; HFD: high-fat diet, ROR: retinoid acid receptor-related orphan receptor, AGEs: advanced glycation end products. ROS: reactive oxygen free radicals; SOD: superoxide dismutase; CAT: catalase; “↑” increased; “↓” decreased.
Figure 3Flavonoids work on each type of damage-dependent trigger of cellular senescence. Cells induced to senesce by damaging insults exhibit higher basal levels of damage than healthy cells and generate damage at a higher rate.
Human clinical trials focusing on aging.
| Flavonoid Therapy | Indication | Dose and Duration | Trial |
|---|---|---|---|
| Quercetin (Q) + Dasatinib (D) | Alzheimer’s disease | Q (1000 mg/day) + D (100 mg/day) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles | NCT04785300 |
| Intermittent D + Q administered for 2 days on/14 days off for 12 weeks (6 cycles) | NCT04063124 | ||
| Age-related osteoporosis | D (100 mg/2 days) plus Q (1000 mg/day last for 3 days) taken orally on an intermittent schedule (starting every 28 days) over 20 weeks, resulting in five total dosing periods throughout the entire intervention | NCT04313634 | |
| Accelerated-ageing-like | Q (1000 mg/day) + D (100 mg/day) administered orally for 3 consecutive days | NCT02652052 | |
| Diabetic kidney disease | Q (1000 mg/day) + D (100 mg/day) administered orally for 3 consecutive days | NCT02848131 | |
| Epigenetic aging | 500 mg Q and 50 mg D oral capsules on Monday, Tuesday, and Wednesday (3 days in a row) for 6 months | NCT04946383 | |
| Fisetin | Age-related osteoporosis | 20 mg/kg/day for three consecutive days, taken orally on an intermittent schedule (starting every 28 days) over 20 weeks, resulting in five total dosing periods throughout the entire intervention | NCT04313634 |
| Elderly syndrome | 20 mg/kg/day, orally for 2 consecutive days | NCT03675724 | |
| Elderly syndrome in old women | 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months | NCT03430037 | |
| Osteoarthritis | Administered orally at 20 mg/kg for 2 consecutive days, followed by 28 days off, then 2 more consecutive days | NCT04210986 | |
| Oral fisetin 20 mg/kg taken for 10 days total | NCT04815902 | ||
| Diabetic and chronic kidney disease | 20 mg/kg/day, orally for 2 consecutive days | NCT03325322 | |
| COVID-19 in hospitalized patients | 20 mg/kg/day, orally for 2 consecutive days | NCT04476953 | |
| COVID-19 in outpatients | 20 mg/kg/day oral for 4 days | NCT04771611 | |
| Coronavirus disease 2019 (COVID-19) in nursing home patients | 20 mg/kg/day, orally for 2 consecutive days | NCT04537299 | |
| Genistein | Alzheimer’s disease | 60 mg of genistein BID for 360 days | NCT01982578 |
| Metabolic syndrome | Genistein capsules of 25 mg each, 50 mg/day | NCT04105023 | |
| Rutin | Type 2 diabetes mellitus | Rutin 60 mg in combination with vitamin C 160 mg three times daily in addition to usual antidiabetic treatment for 8 weeks. | NCT03437902 |